Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

MHRA joins Instagram as part of Yellow Card drive

UK medicines regulator follows in the footsteps of NICE in using the channel

MHRA Instagram

The MHRA has increased its use of social media for its latest campaign to encourage the public to report any suspected side effects from taking over-the-counter medicines.

In joining Instagram, where it is @mhragovuk, the MHRA follows in the footsteps of England and Wales’ HTA body NICE (@nicecomms), which launched on the channel at the beginning of this month.

NICE has focused on AMR and diabetes to date, while the UK medicines regulator has so far been using Instgram to encourage the use of its Yellow Card scheme.

All regulatory reporting systems suffering from under-reporting and the MHRA hopes that its latest campaign will “both raise awareness and help strengthen the system”.

Mick Foy, group manager for MHRA’s Vigilance and Risk Management of Medicines division, said: “our campaign will help the public, patients and healthcare professionals report potential side effects and have confidence that their reports are making a difference.”

The MHRA’s social media campaign, of which its new Instagram account is just one element, is part of Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE), a joint action project funded by the European Union.

22nd November 2017

From: Healthcare

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins Insights

Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...